ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR

摘要

An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulati on is designed to deliver the IBAT inhibitor in the ileum and the HBG Co A reducetase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.